KCNJ10 and myeloid sarcoma: On the other hand, using the peptide-based ELISA, Brill et al. identified KIR4.1 autoantibodies in serum from 21 of 80 MS patients, 10 of 45 NMO patients, and 2 of 32 healthy controls (Brill et al., 2015).